Industries > Pharma > Pain Relieving Drugs Market Forecast 2014-2024
Back to Pharma Reports

Pain Relieving Drugs Market Forecast 2014-2024

Future Prospects for Leading Companies

PUBLISHED: 18 September 2014
PAGES: 323
PRODUCT CODE: PHA0007
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0007 Categories: ,

Pain relieving drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the pain relieving drugs market heading? What are the commercial prospects for this market and related technologies? See what the future holds for painkillers. Visiongain’s new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our 323 page report provides 265 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
•  Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
•  Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these six submarkets to 2024:
•  Narcotic pain relieving drugs
•  Neuropathic pain relieving drugs
•  Treatments for arthritis
•  Non-Narcotic pain relieving drugs
•  Treatments for migraines
•  Other pain relieving drugs

Technologies that improve on the tolerance and dependence issues associated with pain relieving drugs will achieve success. The increasing use of abuse-resistant delivery systems in particular will be a major benefiting factor for pain relieving drugs as a whole.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 28 products including these brands:
•  Celebrex
•  Voltaren
•  Relpax
•  Lyrica
•  Cymbalta
•  Aspirin
•  Zomig
•  Duragesic
•  Oxycontin ER
•  Panadol
•  Lidoderm

Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines.

Discover how high revenues can go. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects for the leading regions and countries?
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
•  US
•  Japan
•  Germany
•  France
•  UK
•  Italy
•  Spain
•  Brazil
•  Russia
•  India
•  China
•  Turkey
•  South Korea
•  Rest of the World

Our analyses show sustained growth, particularly for the BRIC nations of Brazil, Russia, India, and China. New product approvals and the development of abuse-resistant drugs will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Research and development activities
What is happening in the R&D pipeline for pain relieving drugs? You see developmental trends, gaining insight into the R&D pipeline for:
•  Narcotic pain relieving drugs
•  Neuropathic pain relieving drugs
•  Anti-Arthritis pain relieving drugs
•  Non-Narcotic pain relieving drugs
•  Anti-Migraine pain relieving drugs

What issues will affect the pain relieving drugs market?
Our new report discusses issues and events affecting the pain relieving drugs market. You will find discussions of many issues and developments, including:
•  Reimbursement, regulations, patent expiries, generic competition and OTC switching
•  Cost savings and efficiencies
•  Anti-convulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
•  Overcoming drug tolerance and dependence
•  The use of biologics (e.g. monoclonal antibodies, MAbs,) for rheumatoid arthritis (RA)
•  Disease modifying anti-rheumatic drugs (DMARDs)
•  Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
•  Understanding pain pathways and mechanisms of action
•  Safety and patient compliance
•  Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2014 to 2024.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues from 2014 to 2024. The R&D pipeline is strong.
Overall world revenue for that market area will reach $68.2bn in 2014, our report forecasts. Aging populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.  

How the Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies report helps you
In summary our 323 page report gives you the following knowledge:
•  Revenues forecast to 2024 for the overall pain relieving drugs market and 6 submarkets – discover the industry’s prospects, finding promising technology areas for investments and revenues
•  Predicted revenues of 28 leading drugs to 2024 – discover prospects for the leading pain relieving drugs with forecasted revenues provided to 2024
•  Revenue forecasts to 2024 for 13 leading national markets – US, Japan, Germany, France, the UK, Italy, Spain, Brazil, Russia, India, China, Turkey, South Korea and Rest of the World
•  Assess leading companies – hear about products, results and strategies including recent activities and outlook for companies such as GSK, Johnson & Johnson, and Pfizer
•  Review of R&D pipelines – investigate developmental trends and progress
•  Discussion of what stimulates and restrains companies and the market
•  Prospects for established firms and those seeking to enter the market
•  View opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the treatment of pain. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pain Relieving Drugs Market Forecast 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Pain Relieving Drugs Market Forecast 2014-2024


Connect with us

Visiongain Pharma

Visiongain Pharma

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

READ

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

11 January 2021

READ

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

READ

Categories

Category